December 20, 2021
A New Jersey federal judge refused to release a Johnson & Johnson pharmaceutical unit and affiliates from a patent attorney's False Claims Act lawsuit over the prostate cancer treatment Zytiga, reasoning that the lawyer adequately alleged that the company obtained a patent under false pretenses.